Skip to content

Trending News

What Just Happened
4 years agoOptimizeRx Announces Agreement with a Top Pharmaceutical Manufacturer to Use its Evidence-Based Physician Engagement to Solve Lapse in Medical Coverage Barrier for Patients – Stockhouse 4 years agoOM1 Launches Multiple Sclerosis Registry with More than 20000 Patients Prospectively Followed with Deep Clinical Data – Markets Insider 4 years agoReal-World Evidence And Its Use In Advertising Of Medicinal Products In The EU And US – Media, Telecoms, IT, Entertainment – Worldwide – Mondaq News Alerts 4 years agoNational Evaluation System for health Technology Coordinating Center Adds Clinical Laboratory and Patient Engagement Expertise to Governing Committee – Business Wire 4 years agoAbnormal temperatures linked to climate change cause over 740,000 deaths annually in India
Sunday, Jan 19, 2025
Primary Menu
  • Categories
    • Real World Research (RWR)
    • RWD Sources
    • Movers and Shakers
    • RWE – Real World Evidence
    • Health Tech
    • Medical Devices
    • RWR & COVID 19
    • Regulatory
    • Oncology
    • Mental Health
    • Schrödinger’s Donkey
    • Decentralised Trials
    • Recently Released
  • Editorials
  • RWR
  • Newsfeed
  • FAQ
  • ABOUT
    • About RWR News
    • About the Authors
    • RWR News Editorial Policy
  • RESOURCES
    • Phoenix RWR Consulting
    • RedBird Reg Intel Tools
    • RWR Study Master File

Tag: Myeloproliferative neoplasm

  • Home
  • Myeloproliferative neoplasm
Category:
  • Oncology
  • Real World Research (RWR)
  • Recently Released
  • RWE - Real World Evidence

Dr. Verstovsek on Real-World Survival Data With Ruxolitinib in Myelofibrosis – OncLive

CONTEXT:  Brief update and short (2min) webcast from Dr Verstovsek on real-world survival data for patients with myelofibrosis taking ruxolitinib.  Overall patients saw an increased survival benefit of 1 year Continue Reading

Posted On : May 16, 2021 Published By : Ken Ashman

XKCD Mental Break

Coffee Break Cartoon XKCD

We don’t spam! Read more in our privacy policy

Check your inbox or spam folder to confirm your signup and download

Copyright RedBird 2021
Theme: Royal Magazine by ThemeinWP
  • Cookie Policy (EU)
  • Privacy Statement (EU)
  • Impressum
  • Cookie Policy (UK)
  • Privacy Statement (UK)
  • Cookie Policy (US)
  • Cookie Policy (CA)
  • Privacy Statement (CA)
  • Disclaimer
  • Privacy Statement (US)
Manage Cookie Consent
We use cookies to optimize our website and our service.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}